VICTRELIS
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
May 2011
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VICTRELIS (boceprevir) is an oral protease inhibitor approved in 2011 for treating chronic hepatitis C virus (HCV) infection. It works by blocking the HCV NS3/4A serine protease, preventing viral replication. This was a first-generation direct-acting antiviral (DAA) that represented a major advance in HCV treatment before the era of pangenotypic, interferon-free regimens.
LOE Approaching
Declining
1.5 years to LOEProduct is in terminal decline with 1.6 years to patent expiry; brand teams are right-sizing and transitioning to generics management or next-generation portfolio assets.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects
Started Oct 2011
32 enrolled
Healthy
Why This Matters for Your Career
Worked on VICTRELIS at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.